Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) is expected to be posting its results before the market opens on Thursday, November 12th. Analysts expect Zealand Pharma A/S to announce earnings of ($1.5714) per share and revenue of $8.40 million for the quarter.
Zealand Pharma A/S Stock Performance
Zealand Pharma A/S stock opened at $34.63 on Thursday. Zealand Pharma A/S has a 12-month low of $33.08 and a 12-month high of $83.12. The company has a quick ratio of 13.98, a current ratio of 13.98 and a debt-to-equity ratio of 0.02. The business’s 50-day moving average price is $40.13 and its two-hundred day moving average price is $47.55. The stock has a market cap of $2.48 billion, a PE ratio of 5.74 and a beta of 0.99.
Analysts Set New Price Targets
A number of research analysts have recently commented on the stock. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. Zacks Research raised shares of Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a report on Monday, October 12th. Barclays cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Finally, Jefferies Financial Group downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Zealand Pharma A/S currently has an average rating of “Hold”.
View Our Latest Stock Analysis on ZLDPF
About Zealand Pharma A/S
Zealand Pharma A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. Its research is primarily directed toward metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs, often using innovative peptide structures and delivery approaches.
Zealand’s portfolio has included dasiglucagon, a glucagon analogue developed for the treatment of severe hypoglycemia.
Featured Stories
- Five stocks we like better than Zealand Pharma A/S
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
